|This activity is available for free to members of NASP. Visit the top section of www.ProCE.com/CSPE for details.|
A product of the National Association of Specialty Pharmacy's (NASP) Center for Specialty Pharmacy Education(CSPE). View more NASP/CSPE Activities
Renal Cell Carcinoma (RCC) is one of the top ten cancers diagnosed in the United States. RCC is usually diagnosed in people greater than 50 years of age with a slightly greater incidence in men than in women. This activity will review the treatment options for patients with metastatic RCC. The pharmacological treatments available, appropriate use, adverse events, monitoring of agents, and management of adverse events will also be discussed. Future therapies and emerging agents will also be explored.
The target audience for this activity includes pharmacists. Upon completion of this activity, participants will be able to:
- Discuss first-line treatment options for patients with metastatic renal cell carcinoma (RCC).
- Evaluate recent clinical data on emerging agents for the treatment of RCC in the relapsed.
- Summarize side effect management in the treatment of RCC.
Megan Brafford May, Pharm.D., BCOP
Clinical Oncology Pharmacy Specialist
Baptist Health Lexington
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants the existence of any significant financial interest or any other relationship with the manufacturer of any commercial product(s) discussed in an educational presentation. Megan Brafford May does not have any relevant commercial and/or financial relationships to disclose.
Please note: The opinions expressed in this activity should not be construed as those of the CME/CE provider. The information and views are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include unlabeled indications. Use of drugs and devices outside of labeling should be considered experimental and participants are advised to consult prescribing information and professional literature.
Release Date: September 4, 2020
Expiration Date: September 4, 2023
This CE activity is jointly provided by ProCE, Inc. and the National Association of Specialty Pharmacy (NASP). ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-20-204-H01-P has been assigned to this knowledge-based, home-study activity. This CE activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.
No external support has been received for this activity.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.